Peer-Reviewed Publication
bioRxiv2026September 16, 2026Journal Article
Integrative pipeline to profile and target endocrine therapy-insensitive cell populations in ER+ breast cancer.
Svetlana E Semina1, Rosemary J Huggins2,3, Huiping Zhao1,4, Keiko Yanagihara5, Monica Sheinin4,6, Virgilia Macias7, Fatimah Alani1, Leonid Feferman8,9, Andre A Kajdacsy-Balla7, Debra A Tonetti4, Kent F Hoskins10, Geoffrey L Greene3, Jonna Frasor1, Jonathan L Coloff1
1Department of Physiology and Biophysics, University of Illinois Chicago, Chicago, IL, USA.
2Office of Education and Career Development, Comprehensive Cancer Center, University of Chicago Medicine, Chicago, IL, USA.
3Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA.
4Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, IL, USA.
5Department of Breast Surgery and Oncology, Nippon Medical School Tama-Nagayama Hospital, Tokyo, Japan.
6Testing Department, Tempus, Chicago, IL, USA.
7Department of Pathology, University of Illinois Chicago, Chicago, IL, USA.
8Research Informatics Core, Research Resourced Center, University of Illinois Chicago, Chicago, IL, USA.
9Cancer Bioinformatics Shared Resource, University of Illinois Cancer Center, Chicago, IL, USA.
10Division of Hematology/Oncology, University of Illinois Chicago, Chicago, IL, USA.
Abstract
Up to 40% of patients with estrogen receptor positive breast cancer will experience relapse, either while on endocrine therapy (ET) or after ET is completed. A major contributor to ET failure is the presence of ET-insensitive cell populations within tumors. Here, we developed an analytical pipeline to systematically identify and target these populations by integrating single-cell RNA sequencing of…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans